Article

Threats to Truvada Efficacy in HIV Protection

Conference|EADV Congress - European Academy of Dermatology and Venereology Congress

At the 25th European Academy of Dermatology and Venereology Congress in Vienna, Thomas C. Quinn, MD, director of the Johns Hopkins Center for Global Health, discussed the importance of persistence in Truvada use for HIV pre-exposure prophylaxis.

At the 25th European Academy of Dermatology and Venereology Congress in Vienna, Thomas C. Quinn, MD, director of the Johns Hopkins Center for Global Health, discussed the importance of persistence in Truvada use for HIV pre-exposure prophylaxis.

Related Videos
Related Content
FDA Approves Expanded Use for Trikafta in Cystic Fibrosis
December 20th 2024

FDA Approves Expanded Use for Trikafta in Cystic Fibrosis

Aislinn Antrim, Assistant Managing Editor
Public Health Matters: Walmart is Elevating Specialty Pharmacy Services and Enriching HIV Care
July 25th 2024

Public Health Matters: Walmart is Elevating Specialty Pharmacy Services and Enriching HIV Care

Mounjaro tirzepatide GLP-1 receptor agonist vial | Image Credit: © Cynthia - stock.adobe.com
December 20th 2024

FDA Affirms Decision on Tirzepatide Shortage Resolved, Sets Transition Period for Compounding

Alexandra Gerlach, Associate Editor
Pharmacy Focus: World Psychedelics Day
June 14th 2024

Pharmacy Focus: World Psychedelics Day

Ashley Gallagher, Associate Editor
ASHP Midyear: Automated Compounding Workflows and Comprehensive Record-Keeping Reduce Errors
December 19th 2024

ASHP Midyear: Automated Compounding Workflows and Comprehensive Record-Keeping Reduce Errors

Research Shows Efgartigimod Costs Are Far Higher Than Therapeutic Plasma Exchange for Myasthenia Gravis
December 18th 2024

Research Shows Efgartigimod Costs Are Far Higher Than Therapeutic Plasma Exchange for Myasthenia Gravis

Aislinn Antrim, Assistant Managing Editor